Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...
Today, the industry has edged closer to production. But the biggest challenge to widespread deployment is no longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results